雷帕霉素对人胰腺癌细胞SW1990的mTOR信号通路的影响

目的:研究雷帕霉素对人胰腺癌细胞SW1990的mTOR信号通路的影响。方法:采用免疫细胞化学证实mTOR信号通路的存在,通过CCK-8法研究雷帕霉素对胰腺癌细胞增殖的影响,通过Western blot和real time PCR分别从蛋白水平和基因水平研究雷帕霉素对mTOR及其下游分子的表达。结果:免疫细胞化学结果显示p-mTOR、p-p70S6K、p-4E-BP1在细胞质中均呈阳性;CCK-8法显示雷帕霉素能明显抑制细胞增殖(P<0.05);Western blot结果显示随着雷帕霉素浓度的增加,p-mTOR、p-p70S6K表达明显减少,而p-4E-BP1蛋白表达明显增加(P<0.05);Real-time PCR结果显示随雷帕霉素浓度的增加,CyclinD1、VEGF、c-myc基因表达明显减少(P<0.05)。结论:人胰腺癌细胞系SW1990中存在mTOR信号通路并处于激活状态;雷帕霉素抑制胰腺癌细胞增殖与雷帕霉素抑制mTOR信号通路活化有关。     

mTOR信号途径与肿瘤

mTOR信号途径是最近新出现的细胞内重要信号途径,该途径在进化上高度保守,主要通过控制蛋白合成来调节细胞生长。现发现人体某些错构瘤综合征和恶性肿瘤存在mTOR信号途径的异常激活,雷帕霉素及其衍生物是mTOR信号特异性的抑制荆。这些新发现对了解细胞的生长调控和肿瘤的靶向性治疗具有重要意义。     

FAK/mTOR信号通在肿瘤细胞中的调控作用

粘附斑激酶（focal adhesion kinase,FAK）是一种胞质非受体酪氨酸激酶,是整合素信号通路里一个重要的调节因子,在肿瘤细胞中高表达,与细胞迁移、粘附和侵袭有关。mTOR (mammalian target of rapamycin)是非典型性的Ser/Thr激酶,属于PIKK（phosphatidylinositol kinase related kinase）超家族,介导营养信号调控细胞生长、分化及代谢等生理过程。近年的研究发现FAK通过三条途径与mTOR相关联,组成FAK/mTOR信号通路,在肿瘤细胞的增殖、迁移及肿瘤微环境中发挥着重要的调控作用。本文综述了FAK、mTOR和FAK/mTOR信号通路的特点及对肿瘤细胞调控作用的研究概况,为肿瘤治疗提供参考。     

雷帕霉素对糖尿病肾病大鼠足细胞生物学行为及mTOR信号通路的影响

为了探究雷帕霉素对糖尿病肾病大鼠足细胞生物学行为及哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin,mTOR）信号通路的影响,采用链脲霉素腹腔注射构建糖尿病肾病大鼠模型,将正常大鼠体内取出的足细胞设为对照组,模型大鼠体内取出的足细胞设为糖尿病肾病模型组（DN组）,取2 mg·kg^-1雷帕霉素干预DN组足细胞,并将其设为雷帕霉素组（RAPA组）。采用3-（4,5-二甲基噻唑-2）-2,5-二苯基四氮唑溴盐[3-（4,5-dimethylthiahiazo-z-y1）-2,5-diphenytetrazoliumromide,MTT]法检测足细胞增殖水平,Transwell检测细胞迁移和侵袭能力,流式细胞术检测细胞凋亡水平,Western blot法检测上皮-间充质转化标志物[E-钙黏蛋白（E-cadherin）、N-钙黏蛋白（N-cadherin）、波形纤维蛋白（vimentin）]、mTOR和核糖体S6激酶1（S6K1）蛋白表达水平。结果显示,与对照组相比,DN组细胞增殖水平显著被抑制,细胞迁移、侵袭水平显著升高,细胞凋亡率显著增加,上皮-间充转标志物E-cadherin表达显著下调,N-cadherin和Vimentin表达显著上调,mTOR/S6K1信号通路被显著活化（P<0.05）。与DN组相比,RAPA组细胞增殖水平显著升高,细胞迁移、侵袭水平显著降低,细胞凋亡率显著降低,E-cadherin表达显著上调,N-cadherin和Vimentin表达显著下调,mTOR和S6K1的蛋白表达显著被抑制（P<0.05）。结果表明,雷帕霉素通过抑制mTOR信号通路,促进足细胞体外增殖,抑制细胞迁移、侵袭、凋亡和上皮-间充质转化,发挥对糖尿病肾病大鼠足细胞的保护作用。     

mTOR信号通路与癌症治疗

哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)是一种非典型的丝氨酸／苏氨酸蛋白激酶,在细胞的生长、分化、增殖、迁移和存活上扮演了重要的角色。由于mTOR信号转导通路在细胞周期进程中发挥了重要作用,而细胞周期进程调节异常与许多疾病尤其是癌症的发生、发展有关,因此mTOR信号通路的失调可引起多种癌症。mTOR的特异性抑制剂雷帕霉素及其衍生物CCI-779能抑制mTOR的功能,使细胞阻滞在G。期,并引起凋亡。CCI-779作为抗癌药物已分别进入Ⅱ期临床。通过临床实验CCI-779显示出较高的抗癌活性和相对较小的副作用。越来越多的实验证据显示,mTOR信号转导通路的抑制剂可开发成为潜在的肿瘤特异性治疗药物。     

哺乳动物雷帕霉素靶蛋白(mTOR)在小鼠卵母细胞成熟过程中的表达及作用

哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)是一种Ser/Thr激酶,属于PIKK超家族,对调节细胞周期、蛋白质合成等具有重要作用,是细胞生长、增殖、分化、凋亡的中心调控器,但在哺乳动物卵母细胞中的研究还未见报道．以小鼠卵母细胞为研究对象,采用免疫荧光为主要研究方法,对mTOR在小鼠卵母细胞中的表达进行研究,并通过mTOR的特异性抑制剂雷帕霉素( rapamycin,RAPA )对卵母细胞进行处理,对mTOR在卵母细胞成熟过程中的作用进行研究．结果显示：小鼠卵母细胞成熟过程中,生发泡( germinal vesicle,GV )期mTOR主要集中在核膜处表达,生发泡破裂 ( germinal vesicle breakdown,GVBD )后mTOR伴随染色体分布,第二次减数分裂中期( second metaphase,MⅡ期 ) mTOR伴随纺锤体分布;雷帕霉素处理后,小鼠卵母细胞的成熟受到抑制,且这种抑制作用具有浓度依赖性,同时其mTOR的表达部位和形态也发生变化．研究表明,在小鼠卵母细胞成熟过程中,mTOR在各个时期的表达及分布具有阶段特异性,并对小鼠卵母细胞GVBD的发生和第一极体的排放都具有重要作用．     

mTOR信号转导通路抑制剂及其与肿瘤耐药的研究进展

哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin, mTOR)是一种特异性的蛋白激酶,在调控细胞生长、增殖、代谢等多项生命活动中都具有重要意义。mTOR调控功能的失活与异常激活,会导致相关肿瘤和疾病的发生。近年来已有多种mTOR抑制剂用于治疗该信号转导通路异常引起的肿瘤。该文探究多种调控mTOR的信号通路和mTOR抑制剂用于肿瘤治疗的最新进展,还探讨肿瘤细胞对mTOR抑制剂产生耐药性的潜在机制和应对策略。因此,对mTOR信号通路及其调控机制的探索有助于研发全新的肿瘤治疗技术。     

PI3K/AKT/mTOR信号通路及其在卵巢癌治疗中的应用

卵巢癌是女性生殖系统常见的恶性肿瘤,发病率居于妇科恶性肿瘤第三位,死亡率居于妇科恶性肿瘤之首。目前对卵巢癌的标准治疗包括肿瘤细胞减灭术及卡铂和紫杉醇的联合化疗。PI3K/AKT/mTOR信号通路在卵巢癌的细胞增殖、侵袭、细胞周期进展、血管生成及耐药中发挥重要作用,是卵巢癌中最常发生改变的细胞内途径。本文对PI3K/AKT/mTOR信号通路及其在卵巢癌增殖和进展中的影响、PI3K/AKT/mTOR信号通路抑制剂在卵巢癌中的治疗应用做简要综述。     

PI3K/Akt/mTOR信号通路与自噬及肿瘤的关系

自噬是一种以胞质内出现双层膜结构包裹长寿命蛋白和细胞器的自噬体为特征的细胞“自我消化”过程,在维持细胞内稳态、发育、肿瘤发生和感染中发挥重要作用。近来,诸多研究表明,自噬作为一把“双刃剑”,对肿瘤的发生发展既有促进作用,也有抑制作用。PI3K/Akt/mTOR通路由PI3激酶(PI3K)、蛋白激酶B（PKB/Akt）和哺乳动物类雷帕霉素靶蛋白（mTOR）3个作用分子组成,是一个中心的调节机构,对肿瘤细胞的生长与增殖有促进作用,同时对自噬进行抑制。本文就PI3K/Akt/mTOR通路与自噬及肿瘤发生发展的关系作一综述。     

PI3K/Akt/mTOR信号通路与自噬及肿瘤的关系北大核心CSCD

自噬是一种以胞质内出现双层膜结构包裹长寿命蛋白和细胞器的自噬体为特征的细胞"自我消化"过程,在维持细胞内稳态、发育、肿瘤发生和感染中发挥重要作用。近来,诸多研究表明,自噬作为一把"双刃剑",对肿瘤的发生发展既有促进作用,也有抑制作用。PI3K/Akt/m TOR通路由PI3激酶(PI3K)、蛋白激酶B(PKB/Akt)和哺乳动物类雷帕霉素靶蛋白(m TOR)3个作用分子组成,是一个中心的调节机构,对肿瘤细胞的生长与增殖有促进作用,同时对自噬进行抑制。本文就PI3K/Akt/m TOR通路与自噬及肿瘤发生发展的关系作一综述。     

Participation of mTOR in the regulation of multidrug resistance of tumor cells

Molecular mechanisms of the influence of PI3K/Akt/PTEN/mTOR-signaling pathway on survival of tumor cells treated with cytotoxic drugs was studied using rapamycin (Rapa), mTOR specific inhibitor, and 9 human tumor cell lines of different origin and with different Akt kinase activity. Three of these cell lines were selected for drug resistance due to P-glycoprotein (Pgp or ABCB1) overexpression. Rapa inhibited phosphorylation of mTOR downstream effectors. Rapa sensitivity of the cells was Akt-dependent but did not correlate with ABCB1 overexpression. Suppression of mTOR function increased drug resistance in 8 out of 9 cell lines studied. The influence of Rapa on the ABC-transporter gene expression was examined. It was shown that in half of the cell lines studied Rapa exerted differential effects on the amount of ABC-transporter proteins: in some cases the protein amount decreased and in others, increased. The amount of mRNA remained unchanged. These data suggest that mTOR can regulate ABC transporters at the level of translation.     

The integral role of mTOR in lipid metabolism

Comment on: Soliman GA, et al. Lipids 2010; 45:1089-100.     

Phellodendrine promotes autophagy by regulating the AMPK/mTOR pathway and treats ulcerative colitis

To investigate the therapeutic effects of phellodendrine in ulcerative colitis (UC) through the AMPK/mTOR pathway. Volunteers were recruited to observe the therapeutic effects of Compound Cortex Phellodendri Liquid (Huangbai liniment). The main components of Compound Cortex Phellodendri Liquid were analysed via network pharmacology. The target of phellodendrine was further analysed. Caco-2 cells were cultured, and H₂O₂ was used to stimulate in vitro cell model. Expression levels of LC3, AMPK, p-AMPK, mTOR and p-mTOR were detected via Western blotting and through immunofluorescence experiments. The therapeutic effects of phellodendrine were analysed via expression spectrum chip sequencing. The sequencing of intestinal flora further elucidated the therapeutic effects of phellodendrine. Compared with the control group, Compound Cortex Phellodendri Liquid could substantially improve the healing of intestinal mucosa. Network pharmacology analysis revealed that phellodendrine is the main component of Compound Cortex Phellodendri Liquid. Moreover, this alkaloid targets the AMPK signalling pathway. Results of animal experiments showed that phellodendrine could reduce the intestinal damage of UC compared with the model group. Findings of cell experiments indicated that phellodendrine treatment could activate the p-AMPK /mTOR signalling pathway, as well as autophagy. Expression spectrum chip sequencing showed that treatment with phellodendrine could promote mucosal healing and reduce inflammatory responses. Results of intestinal flora detection demonstrated that treatment with phellodendrine could increase the abundance of flora and the content of beneficial bacteria. Phellodendrine may promote autophagy by regulating the AMPK-mTOR signalling pathway, thereby reducing intestinal injury due to UC.     

The role of mTOR signaling pathway in spinal cord injury

The mammalian target of rapamycin (mTOR) signaling pathway plays an important role in multiple cellular functions, such as cell metabolism, proliferation and survival. Many previous studies have shown that mTOR regulates both neuroprotective and neuroregenerative functions in trauma and various diseases in the central nervous system (CNS). Recently, we reported that inhibition of mTOR using rapamycin reduces neural tissue damage and locomotor impairment after spinal cord injury (SCI) in mice. Our results demonstrated that the administration of rapamycin at four hours after injury significantly increases the activity of autophagy and reduces neuronal loss and cell death in the injured spinal cord. Furthermore, rapamycin-treated mice show significantly better locomotor function in the hindlimbs following SCI than vehicle-treated mice. These findings indicate that the inhibition of mTOR signaling using rapamycin during the acute phase of SCI produces neuroprotective effects and reduces secondary damage at lesion sites. However, the role of mTOR signaling in injured spinal cords has not yet been fully elucidated. Various functions are regulated by mTOR signaling in the CNS, and multiple pathophysiological processes occur following SCI. Here, we discuss several unresolved issues and review the evidence from related articles regarding the role and mechanisms of the mTOR signaling pathway in neuroprotection and neuroregeneration after SCI.     

The role of mTOR signaling pathway in spinal cord injury

The mammalian target of rapamycin (mTOR) signaling pathway plays an important role in multiple cellular functions, such as cell metabolism, proliferation and survival. Many previous studies have shown that mTOR regulates both neuroprotective and neuroregenerative functions in trauma and various diseases in the central nervous system (CNS). Recently, we reported that inhibition of mTOR using rapamycin reduces neural tissue damage and locomotor impairment after spinal cord injury (SCI) in mice. Our results demonstrated that the administration of rapamycin at four hours after injury significantly increases the activity of autophagy and reduces neuronal loss and cell death in the injured spinal cord. Furthermore, rapamycin-treated mice show significantly better locomotor function in the hindlimbs following SCI than vehicle-treated mice. These findings indicate that the inhibition of mTOR signaling using rapamycin during the acute phase of SCI produces neuroprotective effects and reduces secondary damage at lesion sites. However, the role of mTOR signaling in injured spinal cords has not yet been fully elucidated. Various functions are regulated by mTOR signaling in the CNS, and multiple pathophysiological processes occur following SCI. Here, we discuss several unresolved issues and review the evidence from related articles regarding the role and mechanisms of the mTOR signaling pathway in neuroprotection and neuroregeneration after SCI.